William J. Edenfield

3.2k total citations
101 papers, 2.1k citations indexed

About

William J. Edenfield is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, William J. Edenfield has authored 101 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 31 papers in Molecular Biology. Recurrent topics in William J. Edenfield's work include Chronic Lymphocytic Leukemia Research (12 papers), Advanced Breast Cancer Therapies (12 papers) and HER2/EGFR in Cancer Research (11 papers). William J. Edenfield is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Advanced Breast Cancer Therapies (12 papers) and HER2/EGFR in Cancer Research (11 papers). William J. Edenfield collaborates with scholars based in United States, Canada and United Kingdom. William J. Edenfield's co-authors include Nancy A. Dawson, John C. Byrd, David J. Shields, Volker W. Stieber, Ann M. Peiffer, Edward G. Shaw, Jeffrey K. Giguere, James Piephoff, Dennis F. Moore and Michael D. Chan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

William J. Edenfield

98 papers receiving 2.1k citations

Peers

Countries citing papers authored by William J. Edenfield

Since Specialization

Citations

This map shows the geographic impact of William J. Edenfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William J. Edenfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William J. Edenfield more than expected).

Fields of papers citing papers by William J. Edenfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William J. Edenfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William J. Edenfield. The network helps show where William J. Edenfield may publish in the future.

Co-authorship network of co-authors of William J. Edenfield

This figure shows the co-authorship network connecting the top 25 collaborators of William J. Edenfield. A scholar is included among the top collaborators of William J. Edenfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William J. Edenfield. William J. Edenfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation. 2024 ·Journal of Clinical Oncology ·Judy S. Wang, David Sommerhalder, Manish Sharma, William J. Edenfield, Kartik Sehgal, Do‐Youn Oh, Yixing Jiang, Joel Michalski, Jeeyun Lee, Hans J. Hammers, Li‐Yuan Bai, Chih‐Hung Hsu, (unknown), Kefei Zhou, Lisa K. Blum, (unknown), (unknown), Hsiao D. Lieu, Vladimir Hanes, Aung Naing	2
2	Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies. 2024 ·Journal of Clinical Oncology ·Minal Barve, Tanner M. Johanns, Niharika B. Mettu, (unknown), William J. Edenfield, (unknown), (unknown), Thomas Schuetz	1
3	Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors 2024 ·ESMO Open ·Bradford A. Perez, Raid Aljumaily, Thomas U. Marron, Michael Shafique, Howard A. Burris, Wade T. Iams, Steven J. Chmura, Jason J. Luke, William J. Edenfield, Davendra Sohal, Xiaoyun Liao, Carsten Boesler, (unknown), (unknown), (unknown), (unknown), (unknown), Scott Antonia	10
4	Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer 2024 ·Cancers ·(unknown), (unknown), (unknown), Moonseong Heo, Julie Martin, William J. Edenfield, Anna V. Blenda	1
5	P2.10A.02 Phase 1/1b Trial of MBRC-101, An Anti-EphA5 Monomethyl Auristatin (MMAE) Antibody Drug Conjugate, In Advanced Refractory Solid Tumors 2024 ·Journal of Thoracic Oncology ·Matthew A. Gubens, Shiraj Sen, Mohamad A. Salkeni, (unknown), Nishant Gandhi, William J. Edenfield, (unknown), Kathryn L. Parsons, I‐Jen Chen, (unknown)	1
6	Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors 2023 ·Cancer Chemotherapy and Pharmacology ·Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha M. Wise‐Draper, Howard Safran, (unknown), William J. Edenfield, Lionel D. Lewis, Lone H. Ottesen, Yan Li, Ganesh Mugundu	1
7	Pattern Analysis of Serum Galectins-1, -3, and -9 in Breast Cancer 2023 ·Cancers ·(unknown), (unknown), Julie Martin, William J. Edenfield, Anna V. Blenda	5
8	622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·David J. Pinato, Ruth Plummer, Martin Gutierrez, Jeffrey Yachnin, (unknown), Martin Højgaard, Knut B. Smeland, William J. Edenfield, Hans Prenen, Lars Ny, Alan Anthoney, Nuria Kotecki, Stefan N. Symeonides, Louis Viviers, (unknown), (unknown), Udai Banerji	3
9	32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer 2022 ·Gynecologic Oncology Reports ·Theresa L. Werner, Nehal J. Lakhani, William J. Edenfield, John L. Hays, Corrine Zarwan, Joseph Buscema, Timothy F. Burns, (unknown), Erika Krasnickas Keeton, Robert A. Burger, Charles Anderson	1
10	A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Amer M. Zeidan, Rachel J. Cook, Rodolfo Bordoni, James R. Berenson, William J. Edenfield, Sanjay Mohan, Gongfu Zhou, (unknown), (unknown), Michael R. Savona	10
11	Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials 2021 ·Cancer Medicine ·Renata Ferrarotto, Ian C. Anderson, Balazs Medgyasszay, M.R. García-Campelo, William J. Edenfield, Trevor Feinstein, Jennifer M. Johnson, Sujith Kalmadi, Philip E. Lammers, (unknown), Yili Pritchett, Shannon R. Morris, Rajesh Malik, Tibor Csőszi	37
12	Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). 2019 ·Journal of Clinical Oncology ·Thomas E. Witzig, Kami J. Maddocks, Sven de Vos, Roger M. Lyons, William J. Edenfield, Jeff P. Sharman, Julie M. Vose, Habte Yimer, Helen Wei, Edward M. Chan, Priti Patel, Christopher Di Simone, Mitul Gandhi, Jennifer Vaughn, Kathryn S. Kolibaba, Bruce D. Cheson, Felipe Samaniego	12
13	ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC). 2019 ·Journal of Clinical Oncology ·Mary‐Ellen Taplin, Arif Hussain, Satish Shah, Neal D. Shore, Manish Agrawal, William R. Clark, William J. Edenfield, Luke T. Nordquist, Oliver A. Sartor, James E. Butrynski, Gurkamal Chatta, Mark T. Fleming, William Oh, (unknown), Jessica Piel, David T. Nash, Gozde Colak, Jian Li, Claudia Lebedinsky, Emmanuel S. Antonarakis	12
14	P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results 2017 ·Journal of Thoracic Oncology ·Lowell L. Hart, Patrick J. Roberts, Renata Ferrarotto, Rodolfo Bordoni, Paul Conkling, Tejas Patil, Caio M. Rocha Lima, Taofeek K. Owonikoko, Steven R. Schuster, Robert M. Jotte, Robert J. Hoyer, (unknown), (unknown), Raid Aljumaily, William J. Edenfield, Alexander I. Spira, Rajesh Malik, Geoffrey I. Shapiro	1
15	A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer 2016 ·Annals of Oncology ·M. Beeram, Sara M. Tolaney, J. Thaddeus Beck, Maura N. Dickler, Alison Conlin, (unknown), Teresa Helsten, Paul Conkling, William J. Edenfield, Donald Richards, (unknown), (unknown), (unknown), Shubham Pant, Kevin Kalinsky, Howard A. Burris, Carlos Becerra, Brent N. Rexer, Shannon L. Puhalla, Matthew P. Goetz	8
16	Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer 2015 ·Clinical Cancer Research ·Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig, Franklin Chu, Роберто Пили, Joseph J. Stephenson, Nicholas J. Vogelzang, Alan J. Koletsky, Luke T. Nordquist, William J. Edenfield, (unknown), Karen J. Ferrante, Mary-Ellen Taplin	64
17	Mechanical Ventilation in Hematopoietic Stem Cell Transplantation 1999 ·CHEST Journal ·Andrew F. Shorr, Lisa K. Moores, William J. Edenfield, (unknown), Thomas M. Fitzpatrick	39
18	Extramedullary Myeloid Cell Tumors in Myelodysplastic-Syndromes: Not a True Indication of Impending Acute Myeloid Leukemia 1996 ·Leukemia & lymphoma ·John C. Byrd, William J. Edenfield, Nancy Dow, Cheryl Aylesworth, Nancy A. Dawson	42
19	Recurrent Helicobacter cinaedi Bacteremia in a Patient Infected with Human Immunodeficiency Virus: Case Report 1995 ·Clinical Infectious Diseases ·M. P. Mammen, Naomi Aronson, William J. Edenfield, Timothy P. Endy	26
20	Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. 1995 ·Journal of Clinical Oncology ·John C. Byrd, William J. Edenfield, David J. Shields, Nancy A. Dawson	445

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact